Current partner codePEPTIDESDE
NCT06397404·Not applicable·OBSERVATIONAL

VExUS in Patients With Acute Heart Failure

Status

Completed

Phase

Not applicable

Enrollment

100

Locations

1

Results

Not posted

Publications

0

Study summary

What the protocol is testing.

The importance of assessing venous congestion in heart failure patients is widely acknowledged, but its study is hampered by the lack of a practical evaluation tool. Venous excess ultrasound score (VExUS) is a promising noninvasive ultrasound-guided modality that can detect and objectify clinically significant organ congestion. VExUS congestion grading score was still not formally validated in patients with AHF, as there is limited data on its clinical application in this group of patients.

Full detailed description

It is currently unknown whether changes in systemic venous congestion, assessed by venous excess ultrasound score (VExUS), are associated with worsening renal function, reduced diuretic and natriuretic response, and poor prognosis in patients with acute decompensation of heart failure (AHF). This prospective, observational, single-center study included patients admitted to the intensive care unit with AHF. At admission all patients undergo bedside Doppler ultrasound of inferior vena cava, hepatic, portal and renal veins to determine blood flow patterns. Congestion was graded with the VExUS score (grade 0, grade 1, grade 2, grade 3). Sodium concentration in a spot urine sample was assessed in 1 hour after first standard intravenous loop diuretic administration. The primary endpoint was the development of acute kidney injury (AKI), defined as oligoanuria (diuresis rate \<0.5 ml/kg/hour for 6 hours) and an increase of serum creatinine \>26 µmol/l within a 48-hour period or 50% from baseline creatinine within a week. The secondary endpoints were in-hospital mortality, change in spot urine sodium content \<50 mmol/l and development of diuretics resistance (defined as the need to double starting dose of intravenous furosemide in 6 hours without adding a different class of diuretic agents).

Interventions

Treatment arms and agents.

DIAGNOSTIC_TEST

Venous excess ultrasound score (VExUS) protocol

All patients upon admission undergo ultrasound assessment of diameter and collapsibility of the inferior vena cava, hepatic vein Doppler, portal vein Doppler, intra-renal venous Doppler.

Timeline

From registration to results.

  1. First posted

    May 2, 2024

  2. Study start

    May 18, 2023

  3. Primary completion

    Nov 25, 2023

  4. Study completion

    Dec 25, 2023

  5. Results posted

    Not reported

  6. Registry updated

    May 20, 2024

Outcomes

What the study measures.

Primary outcomes

Development of acute kidney injury (AKI)

Time frame · During 7 days of hospital stay

Assessment of patient's serum creatinine at admission, in 48 hours, at day 7, and calculation of the amount of urine output in the first 6 h after the administration of a loop diuretic.

Secondary outcomes

In-hospital mortality

Time frame · During patient's hospital stay (up to 14 days)

Death from any cause, whichever came first

Change in spot urine sodium content <50 mmol/l

Time frame · 1 hour after first standard intravenous loop diuretic administration after patient's admission.

Sodium concentration in a spot urine sample is assessed in 1 hour after first intravenous loop diuretic administration. Reduction of natriuretic response in the face of congestion with volume overload with spot urine sodium content \<50 mEq/L generally identifies a patient with an insufficient diuretic response.

Development of diuretics resistance (defined as the need to double initial dose of intravenous furosemide in 6 hours without adding a different class of diuretic agents)

Time frame · 6 hours after first intravenous furosemide administration

Assessment of diuretic response: patient's urine output (ml/kg/hour) in the first 6 hours and patient's medical record with doses of administered diuretics.

Eligibility

Who can take part.

Minimum age
18 Years
Maximum age
100 Years
Sex
ALL
Healthy volunteers
No

Inclusion Criteria: * Acute decompensation of heart failure (diagnosis was based on the European Society of Cardiology (ESC) heart failure guidelines, with patients presenting with dyspnoea at rest or with minimal exertion and signs and symptoms of congestion (rales on chest auscultation, peripheral oedema, swelling of the cervical veins, hepatomegaly, ascites, hepatojugular reflux) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) \> 1000 pg/ml Exclusion Criteria: * Chronic renal replacement therapy or glomerular filtration rate \< 15 ml/min/1.73m 2 (chronic kidney disease Epidemiology Collaboration (CKD)-EPI) * Cirrhosis with portal hypertension * Acute myocardial infarction according to The Fourth Universal Definition of Myocardial infarction * Pulmonary embolism * Sepsis (according to The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)) * Endotracheal intubation at the time of admission * Pregnancy or breastfeeding * Aortic dissection * Active cancer * Neurological or mental disease during exacerbation * Refusal to sign an informed consent form, inadequate acoustic window

Study locations

1 registered sites.

Russia. Showing up to 24 locations stored in the fast local snapshot.

City clinical hospital named after S. S. Yudin, Moscow City Health Department, Moscow, Russian Federation

Moscow, Russia

Publications

Results and literature.

No PMID-linked publications were present in this registry snapshot.

Primary links

Continue at the source.

Related trials

More studies on Nesiritide.

Related PeptideStat pages

Put the record in context.

Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.